KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC
Late-breaking OS results selected for the official.
China’s National Medical Products Administration has accepted the supplemental new drug application seeking the approval of cadonilimab plus chemotherapy for use in the first-line treatment of patients with unresectable locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.
HONG KONG, Jan. 8, 2024 /PRNewswire/ Akeso, Inc. today announced that Michelle Xia, Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the.